JWA
ALXN

JFS Wealth Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

JFS Wealth Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-16
Closed -$2K – 643
2016
Q1 		$2K Buy
+16
New +$2.35K ﹤0.01% 535
2015
Q3 		– Sell
-24
Closed -$4K – 589
2015
Q2 		$4K Sell
24
-3
-11% -$518 ﹤0.01% 428
2015
Q1 		$5K Sell
27
-9
-25% -$1.63K ﹤0.01% 419
2014
Q4 		$7K Buy
+36
New +$6.67K ﹤0.01% 418

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

JFS Wealth Advisors's ALXN Position: Q2 2016 in Review

JFS Wealth Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 16 shares — an estimated $2K sold.

JFS Wealth Advisors first reported a position in ALXN in Q4 2014 and held it in 4 quarters. The position peaked at $7K in Q4 2014. 533 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

  • JFS Wealth Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • JFS Wealth Advisors sold 16 Alexion Pharmaceuticals shares in Q2 2016, an estimated $2K.
  • JFS Wealth Advisors first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 4 quarters.
  • JFS Wealth Advisors's Alexion Pharmaceuticals position peaked at $7K in Q4 2014.
  • 533 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on JFS Wealth Advisors's 13F filing for Q2 2016, filed 25 Jul 2016.